News

In this episode of The Heart Team, which was recorded on-site at AHA 2022, Scott Solomon, MD, takes hosts Jorge Plutzky, MD, and Michael Farkouh, MD, on a deep dive into his experience as a trialist, use of newer medications, and what might be next for the heart failure community.

A recent study highlighted some information on hidradenitis suppurativa patients and their ongoing care needs after being treated in emergency departments.

In this episode of Don't Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, are bringing you insights from the AHA 2022 Scientific Sessions. In the episode, which was recorded on day 2 of the 3-day meeting, our hosts offer listeners perspective on the EMPA-KIDNEY and the TRANSFORM-HF trial, the latter of which Greene served on as an investigator.

A retrospective comparative trial showed that agents including bevacizumab, ranibizumab and aflibercept are linked to similar likelihood of RPE tears.

The trial achieved its primary efficacy endpoint of terminating PSVT with self-administered etripamil, using symptom-based optional repeat dosing.

Dr. Jula Inrig highlights the key data presented at ASN Kidney Week on investigational candidate Sparsentan for IgA nephropathy.

Following a session examining the application of the latest iterations of cardiometabolic health guidelines, Diana Isaacs, PharmD, discusses how the evolving role of diabetes, and recognition of this role, in cardiovascular disease is reflected at the American Heart Association 2022 Scientific Sessions.

Viet Le, PA-C, discusses the results of a study examining characteristics and outcomes among pregnant statin users from EHR data recorded at Intermountain Healthcare medical centers.

Results of the CTS-AMI study presented at AHA 22 suggests tongxiluo, which is an herbal medicine compound used in China, could reduce risk of cardiac events and mortality following a heart attack.

Patients with early VA-ECMO use saw comparable outcomes to those who initially received conservative therapy for hemodynamic stabilization.

A substudy of the PRO-HF study indicates incorporation of KCCQ-12 scores was associated with an improved patient experience and a greater understanding of symptoms.

Education and place of birth contribute the most to the racial and ethnic differences observed in mean CVH score.

The treatment reduced UACR by 37.1% and LDLc by 17.12 compared to placebo.

A single intravenous dose of NTLA-2001 significantly reduced abnormal levels of transthyretin in patients with ATTR amyloid cardiomyopathy, reports new data from AHA 2022.

Low sodium intake is considered less than 2.3 grams per day.

Dr. Demirjian explained suggested changes to how dialysis is conducted in hospital settings.

The late-breaking findings presented at AHA 2022 suggest the incidence of CV events was not lower among patients who received pemafibrate compared with those who received placebo.

Data from the Diuretic Comparison Project suggests chlorthalidone did not provide a reduction in cardiovascular risk or all-cause mortality compared with use of hydrochlorothiazide in older patients with hypertension.

Results of the TRANSFORM-HF trial presented at AHA 22 indicate there were no significant differences in rate of all-cause mortality or hospitalization with the use of torsemide compared with furosemide in people with heart failure.

In a late-breaking abstract presented at ASN 2022, dapagliflozin attenuated the decline in eGFR between month 1-36 compared to placebo.

An analysis of nationally representative data from AHA 2022 suggests most older adults in the US with hypertension were not receiving adequate treatment intensification set forth in US and international guidelines.

National deaths from heart disease spiked in 2020 in the beginning of the COVID-19 pandemic, after an observed steady decline from 2010 to 2019.

Investigators evaluated how the risk of kidney failure and death affects US veterans with chronic kidney disease (CKD) in research presented at Kidney Week 2022 ASN Annual Meeting.

New phase 2 data show a synthetic, proprietary 25 mg dose from COMPASS may fare better for adult patients than a 10 mg dose.

Only 12% of people with CVD older than age 65 used wearable devices, despite estimates suggesting half of all people with CVD are older than age 65.

The 30-year analysis suggests a significantly higher risk associated with lead exposure and lower risk for particulate matter in the US than in the UK.

There are plans for a larger sized study testing zetomipzomib in patients with lupus nephritis.

In a late-breaking abstract, investigators observed a 28% reduction in kidney disease progression or cardiovascular deaths compared to placebo.

With the population aging, there is a need for more home environmental treatment options for patients with kidney disease.

New research presented at Kidney Week 2022 ASN Annual Meeting, demonstrates an association between albuminuria and risk of cognitive problems.